These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 30539680)

  • 1. Biomarkers and pathways of chemoresistance and chemosensitivity for personalized treatment of pancreatic adenocarcinoma.
    Zemanek T; Melichar B; Lovecek M; Soucek P; Mohelnikova-Duchonova B
    Pharmacogenomics; 2019 Jan; 20(2):113-127. PubMed ID: 30539680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts.
    Ruess DA; Görgülü K; Wörmann SM; Algül H
    Drugs Aging; 2017 May; 34(5):331-357. PubMed ID: 28349415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer.
    Frank TS; Sun X; Zhang Y; Yang J; Fisher WE; Gingras MC; Li M
    Cancer Lett; 2015 Jul; 363(1):1-6. PubMed ID: 25890222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic markers for chemosensitivity and chemoresistance in pancreatic cancer--a review.
    Dhayat S; Mardin WA; Mees ST; Haier J
    Int J Cancer; 2011 Sep; 129(5):1031-41. PubMed ID: 21413017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pancreatic cancer subtypes: a roadmap for precision medicine.
    Torres C; Grippo PJ
    Ann Med; 2018 Jun; 50(4):277-287. PubMed ID: 29537309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promising new therapies in advanced pancreatic adenocarcinomas.
    Kundranda M; Kachaamy T
    Future Oncol; 2014 Dec; 10(16):2629-41. PubMed ID: 25531049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent Advances in Pancreatic Cancer: Novel Prognostic Biomarkers and Targeted Therapy-A Review of the Literature.
    Schlick K; Kiem D; Greil R
    Biomolecules; 2021 Oct; 11(10):. PubMed ID: 34680101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current and future biomarkers for pancreatic adenocarcinoma.
    Loosen SH; Neumann UP; Trautwein C; Roderburg C; Luedde T
    Tumour Biol; 2017 Jun; 39(6):1010428317692231. PubMed ID: 28618958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current and Emerging Therapies in Metastatic Pancreatic Cancer.
    Manji GA; Olive KP; Saenger YM; Oberstein P
    Clin Cancer Res; 2017 Apr; 23(7):1670-1678. PubMed ID: 28373365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches.
    Sahin IH; Lowery MA; Stadler ZK; Salo-Mullen E; Iacobuzio-Donahue CA; Kelsen DP; O'Reilly EM
    Expert Rev Gastroenterol Hepatol; 2016 Aug; 10(8):893-905. PubMed ID: 26881472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Translational research in pancreatic ductal adenocarcinoma: current evidence and future concepts.
    Kruger S; Haas M; Ormanns S; Bächmann S; Siveke JT; Kirchner T; Heinemann V; Boeck S
    World J Gastroenterol; 2014 Aug; 20(31):10769-77. PubMed ID: 25152580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets.
    Sclafani F; Iyer R; Cunningham D; Starling N
    Crit Rev Oncol Hematol; 2015 Sep; 95(3):318-36. PubMed ID: 25921418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Therapeutics for Pancreatic Adenocarcinoma.
    Lowery MA; O'Reilly EM
    Hematol Oncol Clin North Am; 2015 Aug; 29(4):777-87. PubMed ID: 26226910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on the management of pancreatic cancer: surgery is not enough.
    Ansari D; Gustafsson A; Andersson R
    World J Gastroenterol; 2015 Mar; 21(11):3157-65. PubMed ID: 25805920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Personalized cancer medicine : Biomarkers for molecular therapy stratification in pancreatic carcinoma].
    Ormanns S
    Pathologe; 2018 Dec; 39(Suppl 2):221-224. PubMed ID: 30361776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic Implications of Molecular Subtyping for Pancreatic Cancer.
    Pishvaian MJ; Brody JR
    Oncology (Williston Park); 2017 Mar; 31(3):159-66, 168. PubMed ID: 28299752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarker-driven and molecularly targeted therapies for pancreatic adenocarcinoma.
    Zhen DB; Coveler A; Zanon S; Reni M; Chiorean EG
    Semin Oncol; 2018 Jun; 45(3):107-115. PubMed ID: 30391013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic and predictive markers in pancreatic adenocarcinoma.
    Le N; Sund M; Vinci A;
    Dig Liver Dis; 2016 Mar; 48(3):223-30. PubMed ID: 26769569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic resistance of pancreatic cancer: Roadmap to its reversal.
    Yu S; Zhang C; Xie KP
    Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188461. PubMed ID: 33157162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging antibodies for the treatment of pancreatic cancer.
    Andrikou K; Peterle C; Pipitone S; Salati M; Cascinu S
    Expert Opin Emerg Drugs; 2017 Mar; 22(1):39-51. PubMed ID: 28253833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.